Type 2 diabetes was revealed by cell transplantation

According to RCO News AgencyAccording to a new clinical study, insulin -producing cells, along with engineered blood -powered cells, successfully revealed type 2 diabetes.

According to New Atlas, this new approach, with more tests, can someday treat the unbearable conditions of type 2 diabetes.

The Langerhans Islands are the only human tissue that produces insulin in response to increased blood sugar levels. In type 2 diabetes, the immune system attacks it and slowly destroys the islands and leads to insulin deficiency.

There is now significant progress for the Langerhans Islands, which is a promising tool for restoring insulin production.

However, a major challenge is the simulation of the blood -rich environment that the islands of Langerhans rely on.

The Langerhans Islands are areas within the pancreas that secrete glucagon, insulin, analin, somatostatin, pancreatic polyps and ghrelin and are of great importance in glucose metabolism. The cells were discovered in the year 6 by a German tractor-traveler Paul Langarans. The Langerra Islands make up one to two percent of the pancreas volume and receive 2 to 5 percent of its blood flow.

Currently, researchers at the Will Cornell Medical Institute (WCM) have conducted a study that transplanted the islands with hematopoietic engineered cells and successfully revealed type 2 diabetes in mice.

“This task introduces the basis of subcutaneous island transplantation as a relatively safe and durable treatment option for type 2 diabetes,” said GE LI.

Currently, the conventional approach to the Langerhans Islands, involving the injection of islands extracted from a donor pancreas to the liver portal, is typically through a thin needle under the skin. The Langerhans Islands in the liver fall into small blood vessels called sinusoids, where they consume oxygen and nutrients through the surrounding tissue for weeks.

Many of these islands can be eliminated due to inflammation, oxygen deficiency and immune attack. Therefore, to prevent the rejection of the islands, immunosuppressive drugs are prescribed in the long run.

The researchers wanted to create a less aggressive approach to allow the donation islands to be in a more accessible place, such as under the skin, which would survive the islands. So they engineered human endothelial cells (ECS), cells in the blood vessels and observed that they collect themselves in a network of veins capable of carrying human blood.

When the Langerhans Islands gathered with them, all their embedded islands were embedded in the newly formed vascular network and formed delicate veins that surrounded and infiltrated by the islands. The islands were also functional and produced insulin in response to glucose introduction.

Next, the researchers transplanted human islands and engineered cells under the skin of diabetic mice. As seen in the laboratory, the transplanted placenta formed a vascular island network, and these mice produced human insulin that normalized blood sugar for more than 6 weeks. This long -term effect in mice effectively shows the researchers that this transplanted method is permanent.

Mice that received only the islands without engineered cells were significantly low in insulin production, and insulin secretion was not responsive to the received glucose.

David Redmond, Assistant Professor of Computing Biology Research at WCM, said: “It was noteworthy that we realized that engineered cells when transplanted to the Langerra Islands, support for islands rich in new veins and even gene activity of cells from cells Endothelial supports natural islands.

Subsequent steps include continuing to work on clinical tests to ensure safe and effective this procedure.

“Finally, the potential to plant these vascular islands for safety and effectiveness in additional clinical models should be examined,” said Dr. Rebecca Craig-Schapiro, an assistant professor of surgery.

The researchers hope that their new transplant approach will be made available to people with type 2 diabetes in the next few years.

Lee said that the technology for treating patients with type 2 diabetes requires numerous obstacles, including sufficient scale of vascular islands and the formulation of approaches to prevent the suppression of the immune system.

This study is published in the journal Science Advances.

The end of the message